<p>Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions</p>-Reference-Cited by-同舟云学术

Pharmacokinetics and Bioequivalence of Two Formulations of Valsartan 80 mg Capsules: A Randomized, Single Dose, 4-Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Published:2020-10 Issue: Volume:Volume 14 Page:4221-4230
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Wu Qingqing,Wang Xiaodong,Chen Qian,Zou Yang,Xu Xiaoyan,Li Tingting,Yu Chen,Zhu Fu,Zhang Kanyin E,Jia Jingying,Liu Yanmei

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference27 articles.

1. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

2. Valsartan

3. Renin-Angiotensin System Blockers and Statins Are Associated With Lower In-Hospital Mortality in Very Elderly Hypertensives

4. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension

5. Federal food, drug, and cosmetic act, chapter v, subchapter a, drugs and devices section 355(j)(8)(B)(i).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Valsartan Mitigates the Progression of Methotrexate-Induced Acute Kidney Injury in Rats via the Attenuation of Renal Inflammation and Oxidative Stress;Journal of Inflammation Research;2024-04

2. Effect of High-Fat Meal on the Pharmacokinetics and Safety of Valsartan/Amlodipine Fixed Dose Combination Tablets in Healthy Subjects;Drug Design, Development and Therapy;2024-01

3. Pharmacokinetics and safety of highly variable valsartan in single-pill combination with amlodipine versus its generic formulation: a randomized, three-cycle, three-sequence, partially replicated crossover phase I bioequivalence clinical trial;Frontiers in Pharmacology;2023-09-07

4. Effect of sacubitril-valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels;TROP J PHARM RES;2023

5. LC–MS/MS approach for simultaneous assessment of hyoscine N‐butyl bromide and ketoprofen in biological fluids and pharmaceuticals;Biomedical Chromatography;2023-03-07